A new type of chemical group in cancer drugs binds to KRAS G12C in both its active and inactive forms by altering a specific water molecule and forcing two protein regions to lock together, preventing the protein from sending growth signals.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether the Glu37-Arg68 salt bridge mechanism is consistently observed across all clinically effective dual-state KRAS G12C inhibitors and correlates with improved clinical outcomes.
A systematic review of all published crystallographic structures of dual-state KRAS G12C inhibitors in complex with GTP-bound KRAS G12C, assessing prevalence of the Glu37-Arg68 salt bridge and correlating its presence with biochemical potency, cellular activity, and clinical response data from published trials.
Whether inhibitors designed to stabilize the Glu37-Arg68 salt bridge improve clinical outcomes compared to inhibitors that do not.
A double-blind, randomized trial of 150+ patients with KRAS G12C-mutant NSCLC comparing a novel inhibitor engineered to maximize Glu37-Arg68 salt bridge formation versus a matched inhibitor lacking this feature, with primary endpoint of objective response rate and secondary endpoint of duration of response.
Whether tumors with mutations near Glu37 or Arg68 show reduced sensitivity to dual-state KRAS G12C inhibitors.
A prospective cohort study of 120+ patients with KRAS G12C-mutant cancers treated with dual-state inhibitors, sequencing KRAS for mutations at Glu37, Arg68, and nearby residues, and correlating mutation status with time to progression and tumor shrinkage.
Whether resistance to dual-state KRAS G12C inhibitors is associated with loss of the Glu37-Arg68 salt bridge due to structural mutations.
A case-control study comparing crystallographic structures of KRAS G12C from 20 patients who responded to dual-state inhibitors (cases) versus 20 who developed resistance (controls), specifically assessing presence/absence of the Glu37-Arg68 salt bridge and nearby residue mutations.
The prevalence of the Glu37-Arg68 salt bridge in crystal structures of KRAS G12C bound to dual-state inhibitors across different chemical scaffolds.
A cross-sectional analysis of all publicly available crystal structures of KRAS G12C bound to dual-state inhibitors (n≥15), quantifying the frequency and geometry of the Glu37-Arg68 salt bridge and its correlation with inhibitor potency.